恩替卡韦联合虎驹乙肝胶囊治疗HBeAg阳性慢性乙型肝炎的疗效分析(1)
【摘要】 目的 研究分析恩替卡韦联合虎驹乙肝胶囊治疗乙型肝炎e抗原(HBeAg)阳性慢性乙型肝炎的效果。方法 100例HBeAg阳性慢性乙型肝炎患者为本次研究对象， 按照随机数字表法分成对照组及治疗组， 每组50例。对照组患者采用恩替卡韦治疗， 治疗组患者采用恩替卡韦联合虎驹乙肝胶囊治疗。比较两组患者治疗12、24、48周时乙肝病毒脱氧核糖核酸(HBV-DNA)、HBeAg阴转率， 随访1年比较两组患者不良反应发生情况。结果 治疗12、48周时， 两组患者的HBV-DNA转阴率比较， 差异均无统计学意义(P>0.05)；治疗24周时， 治疗组患者的HBV-DNA转阴率为76%， 高于对照组的56%， 差异具有统计学意义(P<0.05)。两组患者治疗12、24、48周时的HBeAg阴转率比较， 差异均无统计学意义(P>0.05)。治疗组患者的不良反应发生率为8%， 与对照组的10%比较， 差异无统计学意义(P>0.05)。结论 恩替卡韦联合虎驹乙肝胶囊治疗HBeAg阳性慢性乙型肝炎起效快， 治疗效果肯定， 不良反应少， 值得临床推广。
【关键词】 恩替卡韦；虎驹乙肝胶囊；乙型肝炎e抗原阳性；慢性乙型肝炎；效果
DOI：10.14163/j.cnki.11-5547/r.2017.31.050
【Abstract】 Objective To study and analyze the effect of entecavir combined with Huju hepatitis B capsule in the treatment of hepatitis B e antigen (HBeAg) positive chronic hepatitis B. Methods A total of 100 HBeAg positive chronic hepatitis B patients as study subjects were divided by random number table method into control group and treatment group， with 50 cases in each group. The control group was treated with entecavir， and the treatment group was treated with entecavir combined with Huju hepatitis B capsule. The hepatitis B virus DNA (HBV-DNA) and HBeAg negative-conversion rate were compared between the two groups at 12， 24 and
48 weeks of treatment. After 1 years of follow-up， the occurrence of adverse reactions between the two groups were compared. Results After 12 and 48 weeks of treatment， both groups had no statistically significant difference in HBV-DNA negative-conversion rate (P>0.05). After 24 weeks of treatment， the treatment group had higher HBV-DNA negative-conversion rate as 76% than 56% in the control group， and the difference was statistically significant (P<0.05). Both groups had no statistically significant difference in HBV-DNA negative-conversion rate at 12， 24 and 48 weeks of treatment (P>0.05). The treatment group had no statistically significant difference in incidence of adverse reactions as 8%， comparing with 10% in the control group (P>0.05). Conclusion Combination of entecavir and Huju hepatitis B capsule has the advantages of fast onset， positive efficacy and little adverse reactions. It is worthy of clinical promotion.
【Key words】 Entecavir； Huju hepatitis B capsule； Hepatitis B e antigen positive； Chronic hepatitis B； Effect
我國为慢性乙型肝炎(CHB)的高发国之一， 而在对慢性乙型肝炎的治疗中， 依然依靠慢性乙型肝炎抗病毒治疗控制病情逐渐向肝功能衰竭和肝癌发展的速度， 在对慢性乙型肝炎患者治疗中临床上会用到两大类药物：核苷和核苷酸， 需要患者持续、长期的应用[1， 2]。本文主要研究分析恩替卡韦联合虎驹乙肝胶囊治疗慢性乙型肝炎的效果， 特筛选2014年2月～2016年5月本科室收治的HBeAg阳性慢性乙型肝炎患者100例为本次研究对象， 现将研究资料整理报告如下。, 百拇医药(张忠宝)
【关键词】 恩替卡韦；虎驹乙肝胶囊；乙型肝炎e抗原阳性；慢性乙型肝炎；效果
DOI：10.14163/j.cnki.11-5547/r.2017.31.050
【Abstract】 Objective To study and analyze the effect of entecavir combined with Huju hepatitis B capsule in the treatment of hepatitis B e antigen (HBeAg) positive chronic hepatitis B. Methods A total of 100 HBeAg positive chronic hepatitis B patients as study subjects were divided by random number table method into control group and treatment group， with 50 cases in each group. The control group was treated with entecavir， and the treatment group was treated with entecavir combined with Huju hepatitis B capsule. The hepatitis B virus DNA (HBV-DNA) and HBeAg negative-conversion rate were compared between the two groups at 12， 24 and
48 weeks of treatment. After 1 years of follow-up， the occurrence of adverse reactions between the two groups were compared. Results After 12 and 48 weeks of treatment， both groups had no statistically significant difference in HBV-DNA negative-conversion rate (P>0.05). After 24 weeks of treatment， the treatment group had higher HBV-DNA negative-conversion rate as 76% than 56% in the control group， and the difference was statistically significant (P<0.05). Both groups had no statistically significant difference in HBV-DNA negative-conversion rate at 12， 24 and 48 weeks of treatment (P>0.05). The treatment group had no statistically significant difference in incidence of adverse reactions as 8%， comparing with 10% in the control group (P>0.05). Conclusion Combination of entecavir and Huju hepatitis B capsule has the advantages of fast onset， positive efficacy and little adverse reactions. It is worthy of clinical promotion.
【Key words】 Entecavir； Huju hepatitis B capsule； Hepatitis B e antigen positive； Chronic hepatitis B； Effect
我國为慢性乙型肝炎(CHB)的高发国之一， 而在对慢性乙型肝炎的治疗中， 依然依靠慢性乙型肝炎抗病毒治疗控制病情逐渐向肝功能衰竭和肝癌发展的速度， 在对慢性乙型肝炎患者治疗中临床上会用到两大类药物：核苷和核苷酸， 需要患者持续、长期的应用[1， 2]。本文主要研究分析恩替卡韦联合虎驹乙肝胶囊治疗慢性乙型肝炎的效果， 特筛选2014年2月～2016年5月本科室收治的HBeAg阳性慢性乙型肝炎患者100例为本次研究对象， 现将研究资料整理报告如下。, 百拇医药(张忠宝)